Session Details

W005 Hands-on: Scar Revision

Mon, Mar 10, 9:00 AM - 12:00 PM
W311E
3 CME Available Workshop CCP Restricted Ticketed
View Map

DESCRIPTION

Open admission to eligible categories, no tuition or ticket

This session is tailored to advanced dermatologic surgeons. It offers small group, hands-on experience practicing a variety of surgical scar revision techniques, with faculty engaged in teaching at each table. Z-plasty, geometric broken line closure, and W-plasty will be discussed and performed. Design and execution for repair of ectropion, eclabion, alar notching, melolabial fold distortion, vermillion border distortion, brow distortion and tenting/webbing will be performed. Participants will have the opportunity for realistic hands-on practice with cadaveric arms and heads.

LEARNING OBJECTIVES

1.

Recognize when a z-plasty, geometric broken line closure, or w-plasty can be utilized to improve scar outcome.

2.

Design and execute repair of: ectropion, eclabion, alar notching, melolabial fold distortion, vermillion border distortion, brow distortion, and tenting/webbing.

3.

Implement peri-procedural assessment and strategies for avoidance and management of complications.

SCHEDULE

1:00 PM

Scar Revision

SPEAKERS

Ramona Behshad, MD, FAAD

Ramona Behshad, MD, FAAD

Jerry D. Brewer, MD, MS, FAAD

Jerry D. Brewer, MD, MS, FAAD

Katherine ML Given, MD, PhD, MBA, FAAD

Katherine ML Given, MD, PhD, MBA, FAAD

Stacy McMurray, MD, FAAD

Stacy McMurray, MD, FAAD

Sonul Mehta, MD

Sonul Mehta, MD

SPEAKER DISCLOSURES

Ramona Behshad, MD, FAAD

Castle Biosciences, Inc – Investigator(Grants/Research Funding);

Jerry D. Brewer, MD, MS, FAAD

No financial relationships exist with ineligible companies.

Katherine ML Given, MD, PhD, MBA, FAAD

Avita – Consultant(Other Financial Benefit); Enspectra Health – Consultant (1099 relationship)(Fees); Portal Instruments – Consultant (1099 relationship)(Fees); Retrouvé – Consultant(Other Financial Benefit);

Stacy McMurray, MD, FAAD

No financial relationships exist with ineligible companies.

Sonul Mehta, MD

No financial relationships exist with ineligible companies.